{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:24:13Z","timestamp":1767374653396,"version":"3.44.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01583"],"award-info":[{"award-number":["PI21\/01583"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ad.2025.03.030","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T02:30:30Z","timestamp":1744684230000},"page":"824-829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice"],"prefix":"10.1016","volume":"116","author":[{"given":"B.","family":"Butr\u00f3n-Bris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Llamas-Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Armesto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sahuquillo-Torralba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pujol-Montcus\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Romero-Mat\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Roustan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Vilarrasa-Rull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ferr\u00e1n-Farr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Ovejero-Benito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Palomar-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Navares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Novalbos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Daud\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.03.030_bib0105","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ad.2025.03.030_bib0110","doi-asserted-by":"crossref","first-page":"12793","DOI":"10.3390\/ijms222312793","article-title":"The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications","volume":"22","author":"Singh","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ad.2025.03.030_bib0115","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.ad.2025.03.030_bib0120","doi-asserted-by":"crossref","first-page":"212570","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.ad.2025.03.030_bib0125","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks","volume":"37","author":"Rompoti","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.03.030_bib0130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cge.13186","article-title":"Pharmacogenetics: a strategy for personalized medicine for autoimmune diseases","volume":"93","author":"Tavakolpour","year":"2018","journal-title":"Clin Genet"},{"key":"10.1016\/j.ad.2025.03.030_bib0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-017-0322-9","article-title":"Pharmacogenetics and pharmacogenomics in moderate-to-severe psoriasis","volume":"19","author":"Ovejero-Benito","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.03.030_bib0140","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjd.12331","article-title":"Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B\/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12\/23 blocker ustekinumab","volume":"169","author":"Talamonti","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.03.030_bib0145","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/jdv.19782","article-title":"Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice","volume":"38","author":"Mu\u00f1oz-Aceituno","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.03.030_bib0150","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/exd.14731","article-title":"\u201cSuperresponders\u201d at biologic treatment for psoriasis: a comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ad.2025.03.030_bib0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2025.03.030_bib0160","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.ad.2025.03.030_bib0165","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/bjd.16776","article-title":"Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study","volume":"180","author":"Warren","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.03.030_bib0170","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1468-3083.2011.04325.x","article-title":"Ustekinumab in clinical practice: response depends on dose and previous treatment","volume":"26","author":"Ruiz Salas","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.03.030_bib0175","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/s41419-022-05432-1","article-title":"The role of SPATA2 in TNF signaling, cancer, and spermatogenesis","volume":"13","author":"Masola","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ad.2025.03.030_bib0180","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s10038-024-01227-8","article-title":"Identifying the genetic associations among the psoriasis patients in eastern India","volume":"69","author":"Das","year":"2024","journal-title":"J Hum Genet"},{"key":"10.1016\/j.ad.2025.03.030_bib0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/tpj.2016.64","article-title":"New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Prieto-P\u00e9rez","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.ad.2025.03.030_bib0190","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/pgs-2016-0122","article-title":"Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Prieto-P\u00e9rez","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ad.2025.03.030_bib0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jgg.2015.01.001","article-title":"Association of the late cornified envelope-3 genes with psoriasis and psoriatic arthritis: a systematic review","volume":"42","author":"Shen","year":"2015","journal-title":"J Genet Genomics"},{"key":"10.1016\/j.ad.2025.03.030_bib0200","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/jid.2010.88","article-title":"Deletion of late cornified envelope 3B and 3C genes is not associated with atopic dermatitis","volume":"130","author":"Bergboer","year":"2010","journal-title":"J Invest Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025002777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025002777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T09:12:20Z","timestamp":1756717940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025002777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0001731025002777"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.03.030","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}